Price: $289.7550
$-5.04
-1.708%
|
Day's High:
| $290.57
| Week Perf:
| -5.87 %
|
Day's Low: |
$ 288.81 |
30 Day Perf: |
10.5 % |
Volume (M): |
247 |
52 Wk High: |
$ 346.85 |
Volume (M$): |
$ 71,681 |
52 Wk Avg: |
$299.61 |
Open: |
$290.56 |
52 Wk Low: |
$253.30 |
|
|
Market Capitalization (Millions $) |
157,047 |
Shares
Outstanding (Millions) |
542 |
Employees |
24,000 |
Revenues (TTM) (Millions $) |
32,534 |
Net Income (TTM) (Millions $) |
4,230 |
Cash Flow (TTM) (Millions $) |
-25,730 |
Capital Exp. (TTM) (Millions $) |
974 |
Amgen Inc
Amgen Inc. Overview
Business Nature Amgen Inc. is a leading global biotechnology company that focuses on discovering, developing, manufacturing, and marketing human therapeutics by leveraging advancements in molecular and cellular biology. The company primarily operates in therapeutic areas such as hematology, oncology, and inflammation. Through extensive research and development efforts, Amgen aims to provide innovative solutions that address significant medical needs.
Key Acquisitions and Strategic Position In 2002, Amgen acquired Immunex Corporation for $18 billion, a move that significantly enhanced Amgens presence in the biotechnology sector. This acquisition not only diversified Amgen's product offerings but also enriched its research capabilities in therapeutic proteins and antibodies.
Core Products Amgens renowned products include:
- EPOGEN' (Epoetin alfa) and Aranesp' (darbepoetin alfa): Both of these products stimulate red blood cell production, addressing anemia linked to chronic renal failure and chemotherapy. - Neulasta' (pegfilgrastim) and NEUPOGEN' (Filgrastim): These products support white blood cell production, helping reduce the risk of infection during cancer treatment. - ENBREL' (etanercept): This medication inhibits tumor necrosis factor (TNF), serving as a treatment for autoimmune conditions such as rheumatoid arthritis and psoriatic arthritis.
Other notable products in Amgens portfolio include Kineret' (anakinra) and Stemgen' (Ancestim), which address various medical conditions.
Research and Development Focus Amgens R&D efforts are centered on creating therapeutics in the forms of proteins, monoclonal antibodies, and small molecules across multiple fields including hematology, oncology, inflammation, metabolic and bone disorders, and neuroscience. The company operates with research facilities in the U.S. and clinical development teams deployed in various regions such as Europe, Canada, Australia, and Japan. Amgen maintains a robust pipeline of potential new therapies through both internal research and strategic collaborations.
Manufacturing and Operations The company has commercial manufacturing facilities located in the United States, Puerto Rico, and a distribution center in the Netherlands. Additionally, Amgen collaborates with contract manufacturers, such as Boehringer Ingelheim Pharma KG, to supply some of its high-demand products.
Market Competition Amgen faces competition across its therapeutic categories from other major pharmaceutical companies developing similar products. For instance: - In the anemia treatment space, Aranesp' and EPOGEN' compete with products from Johnson & Johnson, Aventis Pharmaceuticals, and Roche, among others. - For autoimmune disease therapies like ENBREL', Amgen competes with various medications from companies including abbott, Merck, and Pfizer, as well as generics.
Conclusion Amgen Inc. is a pivotal player in the biotechnology industry, strengthening its market position through strategic acquisitions, a diverse product line, and a firm commitment to research and innovation. The company prioritizes advancing human health through targeted therapies and addressing critical health challenges across multiple therapeutic areas.
Company Address: One Amgen Center Drive Thousand Oaks 91320 CA
Company Phone Number: 447-1000 Stock Exchange / Ticker: NASDAQ AMGN
|
|
Customers Net Income fell by |
AMGN's Customers Net Profit Margin fell to |
-35.51 % |
1.95 %
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Business Update
Published Wed, Jan 8 2025 5:55 PM UTC
The field of oncology has seen remarkable innovations in recent years, particularly in the realm of targeted immunotherapy. A significant development has emerged with Asher Biotherapeutics announcing a clinical trial collaboration and supply agreement with Amgen Inc. to investigate etakafusp alfa (formerly known as AB248). This investigational therapy, designed to target CD8...
|
Amgen Inc
AMGN Reports Surge in Revenue But Slips into Loss: What to Expect in the Future Amgen Inc (AMGN) announced a remarkable surge in revenue for the first quarter of 2024, reporting a 21.982% increase to $7.45 billion compared to the corresponding quarter in the previous year. However, the company's performance took an unexpected turn as it slipped into a loss of $-0.21 per share. Despite this setback, Amgen's revenue improvement stands out as the Biotechnology & Pharmaceuticals industries as a whole experienced a significant reduction of -33.39% in business. The earnings per share fell from $1.42 per share, and revenue deteriorated by -9.139% from $8.20 billion. For the fiscal span ending March 31, 2024, Amgen Inc reported a net loss of $-113.000 million, a significant decline from the bottom line of $2,841.000 million in the corresponding quarter a year before. Operating earnings also suffered a substantial drop of -48.41% to $991 million, resulting in a decline in Amgen Inc's operating margin to 13.31% from 31.47% in the first quarter of 2023.
|
Amgen Inc
Amgen Inc's latest financial report for the fourth quarter of 2023 has shown a mixed bag of results, with revenue increasing significantly but earnings per share plummeting. The company reported a 19.842% increase in revenue to $8.20 billion, outperforming many of its counterparts in the Biotechnology & Pharmaceuticals sector. However, earnings per share dropped by -52.98% to $1.42 per share, reflecting a challenging period for the company. One of the key factors contributing to the decrease in earnings per share was the rise in inventories and supplies, which increased to $9,518.0 million. This buildup in inventories may indicate a shift in focus towards improving sales, as the company seeks to meet rising demand. Additionally, the increase in accounts receivable to $7,268.0 million suggests that sales numbers have been strong, further supporting the company's efforts to drive revenue growth.
|
Amgen Inc
Amgen Inc. (AMGN) announced its financial results for the third quarter closing on September 30, 2023. The company reported declining earnings per share (EPS) despite increased revenue. Revenue rose by 3.773% to $6.90 billion compared to $6.65 billion in the same period last year, while income fell by 19.1% to $3.22 per share. In the comparable three months of the previous year, the income per share was $3.98. To assess Amgen Inc.'s performance in the third quarter of 2023, it is important to consider the Biotechnology & Pharmaceuticals industry as a whole. In comparison to its peers, Amgen Inc. fell short, as the industry witnessed top-line growth of 28.59% from the third quarter of 2022. In the prior reporting season, Amgen Inc. recorded revenue of $6.99 billion and a bottom line of $2.57 per share. The bottom line of $1,730.000 million in the fiscal third quarter of 2023 decreased by 19.27% from $2,143.000 million in the corresponding period a year ago.
|
Amgen Inc
Amgen Inc: Accelerated Revenue Growth and Shifting Focus on Sales Amgen Inc, a biotechnology company specializing in the development and manufacturing of innovative pharmaceutical products, recently released its second-quarter financial report for 2023. The report revealed that the company's revenue grew faster than its earnings per share (EPS) during this period. Despite modest growth in bottom-line earnings, Amgen reported a significant increase in revenue, making notable progress in increasing its net income. During the second quarter of 2023, Amgen's revenue increased by 5.945% compared to the corresponding reporting season a year ago, reaching $6.99 billion. This growth is a positive sign for the company, as it indicates increasing demand and sales for its products. However, the bottom-line growth was relatively modest, with earnings per share growing by 4.9% to $2.57 per share. In comparison to the preceding reporting period, Amgen experienced even more substantial advancements. Revenue advanced by 14.431% from $6.11 billion, demonstrating the company's continued growth and success. However, profit during this period plummeted by -51.33% from $5.28 per share. Despite this decline, Amgen managed to achieve a net income of $1,379.000 million, reflecting a 4.71% increase from the net earnings of $1,317.000 million reported in the same financial period a year ago.
|
Per Share |
Current |
Earnings (TTM) |
7.81 $ |
Revenues (TTM) |
60.03 $
|
Cash Flow (TTM) |
- |
Cash |
16.63 $
|
Book Value |
13.89 $
|
Dividend (TTM) |
8.84 $ |
|
Per Share |
|
Earnings (TTM) |
7.81 $
|
Revenues (TTM) |
60.03 $ |
Cash Flow (TTM) |
- |
Cash |
16.63 $
|
Book Value |
13.89 $ |
Dividend (TTM) |
8.84 $ |
|
|
|
Product sales |
|
95.86 % |
of total Revenue |
Product sales U S |
|
70.32 % |
of total Revenue |
Product sales ROW |
|
25.54 % |
of total Revenue |
Prolia |
|
12.29 % |
of total Revenue |
Prolia U S |
|
8.03 % |
of total Revenue |
Prolia ROW |
|
4.26 % |
of total Revenue |
ENBREL |
|
9.7 % |
of total Revenue |
ENBREL U S |
|
9.61 % |
of total Revenue |
ENBREL ROW |
|
0.09 % |
of total Revenue |
XGEVA |
|
6.36 % |
of total Revenue |
XGEVA U S |
|
4.39 % |
of total Revenue |
XGEVA ROW |
|
1.98 % |
of total Revenue |
Repatha |
|
6.67 % |
of total Revenue |
Repatha U S |
|
3.3 % |
of total Revenue |
Repatha ROW |
|
3.36 % |
of total Revenue |
Otezla |
|
6.63 % |
of total Revenue |
Otezla U S |
|
5.41 % |
of total Revenue |
Otezla ROW |
|
1.22 % |
of total Revenue |
TEPEZZA |
|
5.74 % |
of total Revenue |
TEPEZZA U S |
|
5.67 % |
of total Revenue |
TEPEZZA ROW |
|
0.07 % |
of total Revenue |
EVENITY |
|
4.69 % |
of total Revenue |
EVENITY U S |
|
3.4 % |
of total Revenue |
EVENITY ROW |
|
1.29 % |
of total Revenue |
KYPROLIS |
|
4.45 % |
of total Revenue |
KYPROLIS U S |
|
2.8 % |
of total Revenue |
KYPROLIS ROW |
|
1.65 % |
of total Revenue |
Nplate |
|
5.36 % |
of total Revenue |
Nplate U S |
|
4.06 % |
of total Revenue |
Nplate ROW |
|
1.31 % |
of total Revenue |
Aranesp |
|
3.96 % |
of total Revenue |
Aranesp U S |
|
1.23 % |
of total Revenue |
Aranesp ROW |
|
2.73 % |
of total Revenue |
KRYSTEXXA |
|
3.65 % |
of total Revenue |
KRYSTEXXA U S |
|
3.65 % |
of total Revenue |
BLINCYTO |
|
3.85 % |
of total Revenue |
BLINCYTO U S |
|
2.79 % |
of total Revenue |
BLINCYTO ROW |
|
1.06 % |
of total Revenue |
Vectibix |
|
3.32 % |
of total Revenue |
Vectibix U S |
|
1.55 % |
of total Revenue |
Vectibix ROW |
|
1.76 % |
of total Revenue |
TEZSPIRE |
|
3.16 % |
of total Revenue |
TEZSPIRE U S |
|
3.16 % |
of total Revenue |
Other products |
|
16.03 % |
of total Revenue |
Other products U S |
|
11.27 % |
of total Revenue |
Other products ROW |
|
4.76 % |
of total Revenue |
Other revenues |
|
4.14 % |
of total Revenue |
|
|